[{"id":"587353e8-69d4-43ef-a2e4-48bd6a9a08e3","acronym":"NuTide:302","url":"https://clinicaltrials.gov/study/NCT03428958","created_at":"2021-01-19T15:31:48.117Z","updated_at":"2024-07-02T16:35:11.599Z","phase":"Phase 1/2","brief_title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","source_id_and_acronym":"NCT03428958 - NuTide:302","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Vectibix (panitumumab) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/19/2024","primary_completion_date":" 03/19/2024","study_txt":" Completion: 03/21/2024","study_completion_date":" 03/21/2024","last_update_posted":"2024-04-03"},{"id":"6adec79d-70e3-4577-bae0-5f0e8b153dfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05678257","created_at":"2023-01-10T14:58:55.263Z","updated_at":"2024-07-02T16:35:11.773Z","phase":"Phase 2","brief_title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05678257","lead_sponsor":"NuCana plc","biomarkers":" KRAS • BRAF • UGT1A1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • UGT1A1*1*1","tags":["KRAS • BRAF • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-03"},{"id":"2bb68c69-6dfa-4aab-b5ea-dc75b65d4dea","acronym":"NuTide:301","url":"https://clinicaltrials.gov/study/NCT02723240","created_at":"2021-04-20T20:52:51.136Z","updated_at":"2024-07-02T16:35:19.505Z","phase":"Phase 1","brief_title":"NUC-3373 in Advanced Solid Tumours","source_id_and_acronym":"NCT02723240 - NuTide:301","lead_sponsor":"University of Oxford","biomarkers":" KRAS • BRAF • VEGFA","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS • BRAF • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fosifloxuridine nafalbenamide (NUC-3373)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 02/24/2020","primary_completion_date":" 02/24/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2024-02-14"},{"id":"8a6adb38-aff2-48fe-9d34-62af1f2ec96b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05714553","created_at":"2023-06-23T14:09:35.392Z","updated_at":"2024-07-02T16:35:44.820Z","phase":"Phase 1/2","brief_title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT05714553","lead_sponsor":"NuCana plc","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 03/08/2023","start_date":" 03/08/2023","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-06-23"}]